secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cyclerion Therapeutics, Inc. (CYCN)
CIK:        0001755237
Form:       8-K
Filed at:   2022-02-24T23:59:59+00:00
Accession:  0000950170-22-001956
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclerion reports FY2021 net loss $51.6M; MELAS topline data expected Q2 2022
-----------------------------------------------------------------------------

- Net loss $51.6M for FY2021 vs $77.8M in FY2020; cash $54M at Dec 31, 2021.
- R&D expense $37.6M (down from $56.4M); G&A $20.6M (down from $28.8M).
- Phase 2a MELAS trial enrollment closed; topline data expected in Q2 2022.
- Phase 1b CIAS trial enrollment ongoing; topline expected H2 2022; Phase 2a ADv trial initiated.
- Bruce Kinon appointed VP Clinical Development; collaboration with Ariana Pharma for AI biomarker discovery.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/0000950170-22-001956-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1755237/000095017022001956/cycn-20220224.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-001956

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer